Lipocine
LPCN
24 hedge funds and large institutions have $2.73M invested in Lipocine in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 8 closing their positions.
0.17% less ownership
Funds ownership: 0.75% → 0.58% (-0.17%)
17% less funds holding
Funds holding: 29 → 24 (-5)
27% less capital invested
Capital invested by funds: $3.73M → $2.73M (-$1.01M)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$438K |
| 2 |
Renaissance Technologies
New York
|
+$90.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$17.8K |
| 4 |
BlackRock
New York
|
+$7.08K |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$3.13K |
Top Sellers
LPCN Hedge Fund Activity: Q4 2018 in Review
24 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2018, worth a combined $2.73M — down 27% from $3.73M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of LPCN and 3 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 4 added.
The largest buyer was Ameriprise, adding an estimated $438K. The largest seller was Vanguard Group, cutting an estimated $644K.
- 24 institutional investors held Lipocine (LPCN) as of Q4 2018, down from 29 in Q3 2018.
- Funds reported $2.73M of Lipocine stock for Q4 2018, down 27% quarter-over-quarter.
- 3 funds opened new Lipocine positions in Q4 2018 and 8 closed out, a net change of -5 holders.
- The largest Lipocine buyer in Q4 2018 was Ameriprise, an estimated $438K added.
- The largest Lipocine seller in Q4 2018 was Vanguard Group, an estimated $644K sold.
Based on aggregated 13F filings for Q4 2018.